Outcome of metastatic GIST in the era before tyrosine kinase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Tumors
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines

abstract

  • Treatment with imatinib appears to improve 2-year survival of metastatic GIST by approximately 20% when compared to surgery alone. The combination of imatinib and surgery for the treatment of metastatic GIST therefore warrants investigation.

publication date

  • January 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1245/s10434-006-9177-7

PubMed ID

  • 17080234

Additional Document Info

start page

  • 134

end page

  • 42

volume

  • 14

number

  • 1